Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer
Authors
Jung Hyun Jo ; Soo Been Park ; Joowon Chung ; Taeyun Oh ; Hee Seung Lee ; Moon Jae Chung ; Jeong Youp Park ; Seungmin Bang ; Seung Woo Park ; Dawoon E Jung ; Si Young Song
Biliary tract cancer ; Cancer stem cell ; Cancer-associated fibroblasts ; Therapy-resistance ; Transgelin-2
Abstract
Biliary tract cancer (BTC) is a relatively rare but aggressive gastrointestinal cancer with a high mortality rate. Cancer stem cell (CSC) populations play crucial roles in tumor biology and are responsible for the low response to anti-cancer treatment and the high recurrence rate. This study investigated the role of Transgelin-2 (TAGLN2), overexpressed in CSC in BTC cells, and analyzed its expression in patient tissues and serum to identify potential new targets for BTC.